Litcius/Paper detail

859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial

Loren S. Michel, Antonio Jimeno, Ammar Sukari, Thaddeus Beck, Joanne Chiu, E.S. Ahern, John Hilton, Antoine Hollebecque, Sylvie Zanetta, Jyoti D. Patel, Sabeen Mekan, Tzu‐Ching Wu, Ecaterina E. Dumbrava

2023Annals of Oncology10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineClinical endpointAdverse effectHead and neck squamous-cell carcinomaRefractory (planetary science)Phases of clinical researchCohortSurgeryOncologyClinical trialHead and neck cancerCancerAstrobiologyPhysicsCAR-T cell therapy researchLung Cancer Research StudiesPeptidase Inhibition and Analysis
859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial | Litcius